HK1097437A1 - 氧化氮前體的治療應用 - Google Patents
氧化氮前體的治療應用Info
- Publication number
- HK1097437A1 HK1097437A1 HK07101773.4A HK07101773A HK1097437A1 HK 1097437 A1 HK1097437 A1 HK 1097437A1 HK 07101773 A HK07101773 A HK 07101773A HK 1097437 A1 HK1097437 A1 HK 1097437A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nitric oxide
- therapeutic use
- oxide precursor
- precursor
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04016—Carbamoyl-phosphate synthase (ammonia) (6.3.4.16)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/05—Carbon-nitrogen ligases with glutamine as amido-N-donor (6.3.5)
- C12Y603/05005—Carbamoyl-phosphate synthase (glutamine-hydrolysing) (6.3.5.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/323,472 US6346382B1 (en) | 1999-06-01 | 1999-06-01 | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1097437A1 true HK1097437A1 (zh) | 2007-06-29 |
Family
ID=23259343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07101773.4A HK1097437A1 (zh) | 1999-06-01 | 2007-02-14 | 氧化氮前體的治療應用 |
Country Status (8)
Country | Link |
---|---|
US (4) | US6346382B1 (zh) |
EP (4) | EP2361621B1 (zh) |
AU (1) | AU5455600A (zh) |
DK (1) | DK1690535T3 (zh) |
ES (1) | ES2539272T3 (zh) |
HK (1) | HK1097437A1 (zh) |
PT (1) | PT1690535E (zh) |
WO (1) | WO2000073322A1 (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9486429B2 (en) * | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US6346382B1 (en) * | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
US6627199B1 (en) * | 1999-07-09 | 2003-09-30 | Amgen Inc | Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family |
US6596489B2 (en) | 2001-03-30 | 2003-07-22 | Applied Gene Technologies | Methods and compositions for analyzing nucleotide sequence mismatches using RNase H |
US20030224380A1 (en) * | 2001-10-25 | 2003-12-04 | The General Hospital Corporation | Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases |
WO2003054143A2 (en) * | 2001-10-25 | 2003-07-03 | Neurogenetics, Inc. | Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases |
EP1355159A1 (de) * | 2002-04-19 | 2003-10-22 | B.R.A.H.M.S Aktiengesellschaft | Verwendungen von Fragmenten der Carbamoylphosphat Synthetase 1 (CPS 1) für die Diagnose von Entzündungserkrankungen und Sepsis |
DE102004045705A1 (de) | 2004-09-21 | 2006-04-06 | B.R.A.H.M.S Ag | Verwendungen der Carbamoylphosphat Synthetase 1(CPS) als humoraler Biomarker für die Diagnose von Tumorerkrankungen und chronisch entzündlichen Darmerkrankungen |
DE102006021406B4 (de) * | 2006-05-08 | 2008-08-07 | B.R.A.H.M.S Aktiengesellschaft | In vitro Verfahren zur Früherkennung von arznei- und suchtmittelinduzierten Leberschäden und zur Erkennung der bereits erreichten Stufe der Leberschädigung |
KR20170005155A (ko) | 2008-01-31 | 2017-01-11 | 반더빌트유니버시티 | 폐의 용태에 따른 치료 방법 |
CN102369006A (zh) * | 2008-01-31 | 2012-03-07 | 范德比尔特大学 | 治疗冠状动脉和动脉的动脉瘤性蛛网膜下腔出血的方法和组合物 |
DK3338765T3 (en) * | 2009-12-01 | 2019-03-04 | Translate Bio Inc | STEROID DERIVATIVE FOR THE SUPPLY OF MRNA IN HUMANGENETIC DISEASES |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
PL2717893T3 (pl) | 2011-06-08 | 2019-12-31 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby do dostarczania mRNA |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2911677T3 (es) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos |
RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US20140010861A1 (en) | 2012-04-02 | 2014-01-09 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
ES2689523T3 (es) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Composiciones a base de ARNM del gen CFTR y métodos y usos relacionados |
BR112015022660A2 (pt) | 2013-03-14 | 2017-10-31 | Shire Human Genetic Therapies | métodos para a purificação de rna mensageiro |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
EP3501605B1 (en) | 2013-10-22 | 2023-06-28 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
EA201992208A1 (ru) | 2013-10-22 | 2020-07-31 | Транслейт Био, Инк. | ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
CN110511927A (zh) | 2014-04-25 | 2019-11-29 | 川斯勒佰尔公司 | 信使rna的纯化方法 |
US11102994B2 (en) * | 2014-08-21 | 2021-08-31 | Clearfast Inc. | Pre-operative carbohydrate-rich beverage composition and methods of treatment |
EP3313390A4 (en) | 2015-06-29 | 2019-02-20 | Vanderbilt University | INTRAVENOUS CITRULLINE ADMINISTRATION DURING SURGICAL INTERVENTION |
EP3367975A4 (en) * | 2015-10-28 | 2019-08-07 | Launchpad Medical, LLC | COMPOSITIONS AND METHODS FOR THE REGENERATION OF BONE TISSUE |
US10265286B2 (en) | 2016-12-28 | 2019-04-23 | Vanderbilt University | Sequelae of cardiopulmonary bypass-induced pulmonary injury |
AR111082A1 (es) * | 2017-02-27 | 2019-05-29 | Univ Vanderbilt | Citrulina para el tratamiento de la crisis de células falciformes |
EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
US11173190B2 (en) | 2017-05-16 | 2021-11-16 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US20220162278A1 (en) * | 2019-02-27 | 2022-05-26 | The Regents Of The University Of Michigan | Carbamoyl phosphate synthatase-1 for the treatment and prevention of liver injury |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA716628B (en) * | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
NL8102724A (nl) | 1980-07-11 | 1982-02-01 | Stamicarbon | Werkwijze voor de bereiding van copolymeren van etheen met tenminste een ander 1-alkeen. |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5573933A (en) | 1987-04-14 | 1996-11-12 | Luminis Pty, Ltd. | Transgenic pigs |
US4996236A (en) * | 1988-06-22 | 1991-02-26 | Takeda Chemical Industries, Ltd. | Therapeutic composition for hepatic encephalopathy |
US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
US5489742A (en) | 1990-10-23 | 1996-02-06 | Board Of Regents, The University Of Texas System | Transgenic rats and animal models of inflammatory disease |
CA2096723C (en) | 1990-12-04 | 2006-03-28 | Mien-Chie Hung | Methods and compositions for the suppression of neu mediated transformation |
US5643567A (en) | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
US5641484A (en) | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
DE69133575T2 (de) * | 1990-12-05 | 2008-04-17 | The General Hospital Corp., Boston | Verwendung von NO zur Behandlung der persistenten pulmonaren Hypertonie des Neugeborenen |
US5550316A (en) | 1991-01-02 | 1996-08-27 | Fox Chase Cancer Center | Transgenic animal model system for human cutaneous melanoma |
US5550024A (en) * | 1991-04-19 | 1996-08-27 | Biotechnology Research & Development Corporation | Genetic markers for pig litter size |
US5374651A (en) | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
US5286739A (en) * | 1991-09-27 | 1994-02-15 | Board Of Regents, University Of Texas System | Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
US5285940A (en) * | 1992-08-03 | 1994-02-15 | Goulter Victor H | Folding neck-supported food tray |
US5385940A (en) | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
WO1994016740A1 (en) | 1993-01-29 | 1994-08-04 | Brigham And Women's Hospital | The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5646008A (en) | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
US5625125A (en) | 1994-08-09 | 1997-04-29 | Dnx Biotherapeutics | Phospholipase A2 expressing transgenic animals |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5648061A (en) | 1995-05-24 | 1997-07-15 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
US5895788A (en) * | 1996-01-31 | 1999-04-20 | The Board Of Trustees Of The University Of Arkansas | Use of L-arginine and salts thereof in drinking water for the prevention and/or treatment of pulmonary hypertension syndrome in avians |
US5874471A (en) | 1997-02-27 | 1999-02-23 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
CA2306096A1 (en) | 1997-10-15 | 1999-04-22 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
US6796966B2 (en) | 1997-10-15 | 2004-09-28 | Jeffrey E. Thomas | Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal |
US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
US20020068365A1 (en) | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
US6346382B1 (en) * | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US6182295B1 (en) | 1999-06-14 | 2001-02-06 | Kevin Sciglia | Hat |
JP3506114B2 (ja) | 2000-01-25 | 2004-03-15 | 株式会社ニコン | モニタ装置及びこのモニタ装置を具えた研磨装置及び研磨方法 |
US6689810B2 (en) * | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
EP1448600A4 (en) | 2001-09-07 | 2004-12-22 | Bristol Myers Squibb Co | POLYNUCLEOTIDE ENCODING A NOVEL HUMAN G PROTEIN-RELATED RECEPTOR, HGPRMBY39 |
US20030134332A1 (en) | 2001-11-28 | 2003-07-17 | Boykin Joseph V. | Diagnosis of endothelial dysfunction by nitric oxide bioactivity index |
ATE538814T1 (de) | 2005-01-06 | 2012-01-15 | Discovery Lab Inc | Dosierungsschema unter verwendung eines tensids zur behandlung oder verhinderung von lungendysplasien |
EP1957657A4 (en) | 2005-12-01 | 2009-02-18 | Nps Pharma Inc | BIOMARKER OF ENHANCED INTESTINAL FUNCTION |
CN102369006A (zh) | 2008-01-31 | 2012-03-07 | 范德比尔特大学 | 治疗冠状动脉和动脉的动脉瘤性蛛网膜下腔出血的方法和组合物 |
KR20170005155A (ko) | 2008-01-31 | 2017-01-11 | 반더빌트유니버시티 | 폐의 용태에 따른 치료 방법 |
-
1999
- 1999-06-01 US US09/323,472 patent/US6346382B1/en not_active Expired - Lifetime
-
2000
- 2000-06-01 DK DK06005642.1T patent/DK1690535T3/en active
- 2000-06-01 EP EP10185406.5A patent/EP2361621B1/en not_active Expired - Lifetime
- 2000-06-01 EP EP00939475A patent/EP1187844A4/en not_active Withdrawn
- 2000-06-01 AU AU54556/00A patent/AU5455600A/en not_active Abandoned
- 2000-06-01 ES ES06005642.1T patent/ES2539272T3/es not_active Expired - Lifetime
- 2000-06-01 EP EP20060005642 patent/EP1690535B1/en not_active Expired - Lifetime
- 2000-06-01 US US09/585,077 patent/US6743823B1/en not_active Expired - Lifetime
- 2000-06-01 PT PT60056421T patent/PT1690535E/pt unknown
- 2000-06-01 EP EP10185438A patent/EP2335693A3/en not_active Ceased
- 2000-06-01 WO PCT/US2000/015079 patent/WO2000073322A1/en not_active Application Discontinuation
-
2007
- 2007-02-14 HK HK07101773.4A patent/HK1097437A1/zh not_active IP Right Cessation
-
2008
- 2008-05-16 US US12/122,117 patent/US8188147B2/en not_active Expired - Fee Related
-
2012
- 2012-04-25 US US13/456,014 patent/US8536225B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6346382B1 (en) | 2002-02-12 |
US20080234379A1 (en) | 2008-09-25 |
EP1187844A4 (en) | 2003-09-03 |
US8188147B2 (en) | 2012-05-29 |
EP2361621A1 (en) | 2011-08-31 |
DK1690535T3 (en) | 2015-06-29 |
EP1690535B1 (en) | 2015-04-29 |
US20120252895A1 (en) | 2012-10-04 |
WO2000073322A1 (en) | 2000-12-07 |
EP2335693A2 (en) | 2011-06-22 |
US6743823B1 (en) | 2004-06-01 |
EP2361621B1 (en) | 2017-08-09 |
AU5455600A (en) | 2000-12-18 |
EP1187844A1 (en) | 2002-03-20 |
US8536225B2 (en) | 2013-09-17 |
EP1690535A3 (en) | 2007-07-18 |
EP2335693A3 (en) | 2011-09-28 |
ES2539272T3 (es) | 2015-06-29 |
EP1690535A2 (en) | 2006-08-16 |
PT1690535E (pt) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1097437A1 (zh) | 氧化氮前體的治療應用 | |
AU7362201A (en) | Enhancing therapeutic effectiveness of nitric oxide inhalation | |
IL144954A0 (en) | Quinazolines and therapeutic use thereof | |
EP1404343A4 (en) | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES | |
EP1207811A4 (en) | STAIN OXIDE RELEASE MEDICAL ARTICLES | |
GB2414183B (en) | Delivery of nitric oxide for therapeutic treatment | |
AU1451902A (en) | Inhalation of nitric oxide | |
HUP0202150A3 (en) | Use of nitric oxide donors for inducing neurogenesis | |
EP1154997A4 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | |
IL147891A0 (en) | Topical use of anti-muscarnic agents | |
AU2003298551A8 (en) | Nitric oxide and its biomedical significance | |
GB0119025D0 (en) | Compounds and their therapeutic use | |
HUP0105310A3 (en) | Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections | |
HUP0203065A3 (en) | Use of nitric oxide for the treatment of airway constriction | |
GB9922710D0 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis | |
GB0018887D0 (en) | Compound and their therapeutic use | |
GB0024517D0 (en) | Use of medicaments | |
EP1451308A4 (en) | THERAPEUTIC USE OF AZIRIDINO COMPOUNDS | |
GB9911238D0 (en) | Therapeutic use | |
GB0112236D0 (en) | Compounds and their therapeutic use | |
GB0112237D0 (en) | Compounds and their therapeutic use | |
EP1158991A4 (en) | ASTHMA TREATMENT | |
AU2002350212A8 (en) | Pharmaceutically active compounds and methods of use thereof | |
GB9924831D0 (en) | Use of interferon alpha for treatment of asthma | |
GB9926528D0 (en) | Therapeutic use and formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190601 |